{"success":true,"data":{"pressRelease":{"id":"175278","rtpr_id":"nGNX4rtqPX-20261021","ticker":"IVVD","exchange":"NASDAQ","all_tickers":["IVVD"],"title":"Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026","author":"Globe Newswire","published_at":"2026-10-21T11:01:00.109Z","article_body":"* VMS063 is a novel, potential first- and best-in-class monoclonal antibody\ninvestigational candidate discovered by Invivyd \n* VMS063 demonstrated potent in vitro antiviral activity against contemporary\nmeasles virus variants, and attractive biophysical properties supporting its\npotential utility for both treatment and prevention of measles\n* Invivyd is scaling up production toward clinical development in 2027\n* There are currently no FDA approved treatments for measles, leaving a major\ngap in the public health and medical management of measles\n* The U.S. is experiencing a record-breaking number of measles cases in 2026,\nand a significant immunity gap has emerged, leaving millions of Americans\nvulnerable to measles infection and associated complications\nNEW HAVEN, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq:\nIVVD) today announced the presentation of preclinical data describing its\nnovel, potential first- and best-in-class investigational monoclonal antibody\ncandidate VMS063 at IDWeek 2026™ in Washington, D.C. Data demonstrated\nhighly potent in vitro antiviral activity against contemporary measles fusion\nprotein (MeV-F) variants, supporting its potential utility for both treatment\nand prevention (pre/post-exposure prophylaxis) of measles.\n\nVMS063 is a highly potent, half-life-extended, high resistance barrier measles\nmonoclonal antibody candidate engineered via Invivyd’s proprietary antibody\ndiscovery platform to target a highly conserved protein of measles virus.\nVMS063 could be the first precision therapy for measles, as well as a\npotentially important direct immunization option to supplement, offer an\nalternative to, or enhance standard measles vaccination. As a potential\nmeasles prophylactic option, Invivyd intends to maximize the convenience of\naccessing antibody immunization versus measles virus by developing VMS063 in\neither intramuscular or subcutaneous forms. Invivyd has begun manufacturing\nscale-up toward clinical development in 2027.\n\n“Despite continued transmission of measles globally, and a reemergence in\nthe United States, physicians who see measles patients have long lamented that\nthere are no targeted approved treatments for measles. More generally, there\nhas been little, if any, innovation in how we prevent and treat measles since\n1963. As we see more and more cases, it’s clear that Americans, as well as\nthe international community, need additional prevention options for measles as\nwell as a specific treatment,” said Michael Mina, M.D., Ph.D., Chief Medical\nOfficer and Chief Epidemiologist of Invivyd and widely cited measles\nresearcher.  “A molecule like VMS063 has the potential to transform the\nmeasles landscape by leveraging the extraordinary potential of monoclonal\nantibodies that can, with one molecule, provide both prevention and treatment\nto fill these gaps. We are excited to interact with the scientific and public\nhealth community at IDWeek 2026™, as well as leaders across public health\nmore generally, and we are rapidly advancing this program toward clinical\ndevelopment.”\n\nAt IDWeek 2026™, Invivyd will present data describing that VMS063 binds a\nhighly conserved epitope of the MeV-F protein, stabilizing its pre-fusion\nconformation, supporting a mechanism of neutralization through inhibition of\nmembrane fusion. Invivyd characterized the properties of VMS063 including its\nhighly potent in vitro neutralization activity against historical and\ncontemporary MeV variants, including the highest circulating contemporary\ngenotypes, B3 and D8, in both authentic virus and pseudovirus neutralization\nassays.\n\nThe United States is facing a critical measles virus inflection point in 2026,\nwith measles incidence reaching levels not seen in decades. As of October\n2026, U.S. disease burden is nearly double that seen in 2025. As pediatric and\ncommunity vaccination rates dip, a significant immunity gap has emerged. More\nthan nine million school-aged children are estimated to be unprotected against\nmeasles in the U.S. today along with many millions more adults who are immune\ncompromised. More, as one of the most infectious viruses known to exist, and a\nvirus uniquely capable of destroying human immunologic memory, measles has the\npotential to impose a substantial burden on the healthcare system as infection\nspreads.  \n\nIDWeek 2026™ is an annual meeting of the Infectious Diseases Society of\nAmerica (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the\nHIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society\n(PIDS). IDWeek features the latest science and bench-to-bedside approaches in\nprevention, diagnosis, treatment and epidemiology of infectious diseases,\nincluding HIV, across the lifespan. IDWeek 2026™ takes place Oct. 21-24 at\nthe Walter E. Washington Convention Center (801 Allen Y. Lew Place NW) in\nWashington, D.C. For more information, visit www.idweek.org.\n\nAbout VMS063\nVMS063 is a novel, highly potent, half-life-extended, high resistance barrier\nmeasles monoclonal antibody candidate engineered via Invivyd’s proprietary\nantibody discovery platform to target a highly conserved protein of measles\nvirus. VMS063 targets the measles Fusion (F) protein and is designed to lock\nthe trimeric measles Fusion protein into a pre-fusion configuration, thereby\npreventing cell entry, similar to approved pediatric respiratory syncytial\nvirus (RSV) monoclonal antibodies. VMS063 could be the first precision therapy\nfor measles, as well as a potentially important passive preventive option to\nsupplement or enhance measles vaccination.\n\nAbout Invivyd \nInvivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to\ndelivering protection from serious viral infectious diseases, beginning with\nSARS-CoV-2. Invivyd deploys a proprietary integrated technology platform\nunique in the industry designed to assess, monitor, develop, and adapt to\ncreate best in class antibodies. In March 2024, Invivyd received emergency use\nauthorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its\npipeline of innovative antibody candidates. Visit https://invivyd.com/ to\nlearn more.\n\nTrademarks are the property of their respective owners.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Words such as\n“anticipates,” “believes,” “could,” “expects,”\n“estimates,” “future,” “intends,” “plans,” “potential,”\n“predicts,” “projects,” and “targets” or similar expressions (as\nwell as other words or expressions referencing future events, conditions, or\ncircumstances) are intended to identify forward-looking statements.\nForward-looking statements include statements concerning, among other things,\nplans related to the company’s measles program, and the potential of VMS063\nas a novel, potential first- and best-in-class mAb candidate being developed\nfor the treatment and prevention of measles; the potential for VMS063 to be\nthe first precision therapy for measles and a potentially important direct\nimmunization option to supplement, offer an alternative to, or enhance\nstandard measles vaccination; the company’s anticipated development and\nclinical timeline for VMS063; expectations regarding the public health\nenvironment and potential of a molecule like VMS063 to transform the measles\nlandscape; the company’s plans to develop VMS063 in either intramuscular or\nsubcutaneous forms; the company’s strategies and objectives; the company’s\nfuture prospects; and other statements that are not historical fact. The\ncompany may not actually achieve the plans, intentions, or expectations\ndisclosed in the company’s forward-looking statements, and you should not\nplace undue reliance on the company’s forward-looking statements. These\nforward-looking statements involve risks and uncertainties that could cause\nthe company’s actual results to differ materially from the results described\nin or implied by the forward-looking statements, including, without\nlimitation: the timing, progress, and results of the company’s discovery and\npreclinical development activities, including with respect to VMS063; whether\nor not any preclinical candidate identified by the company is determined to be\nsuitable for clinical development; the risk that results of nonclinical\nstudies or clinical trials may not be predictive of future results, and\ninterim data are subject to further analysis; unexpected safety or efficacy\ndata observed during preclinical studies or clinical trials; the\npredictability of clinical success of the company’s product candidates based\non neutralizing activity in nonclinical studies and the assessment of other in\nvitro properties; potential variability in neutralizing activity of product\ncandidates tested in different assays, such as pseudovirus assays and\nauthentic assays; the company’s reliance on third parties; uncertainties\nrelated to the regulatory authorization or approval process, and available\ndevelopment and regulatory pathways; changes in the regulatory environment;\nthe risk that a lack of awareness of mAb therapies and regulatory scrutiny of\nmAb therapies may adversely impact the development or commercial success of\nthe company’s product candidates; changes in expected or existing\ncompetition; the company’s reliance on third parties; complexities of\nmanufacturing mAb therapies; macroeconomic and political uncertainties; and\nwhether the company has adequate funding to meet future operating expenses and\ncapital expenditure requirements. Other factors that may cause the company’s\nactual results to differ materially from those expressed or implied in the\nforward-looking statements in this press release are described under the\nheading “Risk Factors” in the company’s Annual Report on Form 10-K for\nthe year ended December 31, 2025, and its Quarterly Report on Form 10-Q for\nthe quarter ended June 30, 2026, each as filed with the Securities and\nExchange Commission (SEC), and in the company’s other filings with the SEC,\nand in its future reports to be filed with the SEC and available at\nwww.sec.gov. Forward-looking statements contained in this press release are\nmade as of this date, and Invivyd undertakes no duty to update such\ninformation whether as a result of new information, future events or\notherwise, except as required under applicable law.\n\nThis press release contains hyperlinks to information that is not deemed to be\nincorporated by reference in this press release.\n\nContacts:\n\nMedia Relations \n(781) 208-0160\nmedia@invivyd.com\n\nInvestor Relations \n(781) 208-1747\ninvestors@invivyd.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7bf12f50-1073-4ce7-81ac-89426c07add3)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4rtqPX-20261021","title":"Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026","author":"Globe Newswire","ticker":"IVVD","created":"2026-10-21T11:01:00.109Z","tickers":["IVVD"],"exchange":"NASDAQ","article_body":"* VMS063 is a novel, potential first- and best-in-class monoclonal antibody\ninvestigational candidate discovered by Invivyd \n* VMS063 demonstrated potent in vitro antiviral activity against contemporary\nmeasles virus variants, and attractive biophysical properties supporting its\npotential utility for both treatment and prevention of measles\n* Invivyd is scaling up production toward clinical development in 2027\n* There are currently no FDA approved treatments for measles, leaving a major\ngap in the public health and medical management of measles\n* The U.S. is experiencing a record-breaking number of measles cases in 2026,\nand a significant immunity gap has emerged, leaving millions of Americans\nvulnerable to measles infection and associated complications\nNEW HAVEN, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq:\nIVVD) today announced the presentation of preclinical data describing its\nnovel, potential first- and best-in-class investigational monoclonal antibody\ncandidate VMS063 at IDWeek 2026™ in Washington, D.C. Data demonstrated\nhighly potent in vitro antiviral activity against contemporary measles fusion\nprotein (MeV-F) variants, supporting its potential utility for both treatment\nand prevention (pre/post-exposure prophylaxis) of measles.\n\nVMS063 is a highly potent, half-life-extended, high resistance barrier measles\nmonoclonal antibody candidate engineered via Invivyd’s proprietary antibody\ndiscovery platform to target a highly conserved protein of measles virus.\nVMS063 could be the first precision therapy for measles, as well as a\npotentially important direct immunization option to supplement, offer an\nalternative to, or enhance standard measles vaccination. As a potential\nmeasles prophylactic option, Invivyd intends to maximize the convenience of\naccessing antibody immunization versus measles virus by developing VMS063 in\neither intramuscular or subcutaneous forms. Invivyd has begun manufacturing\nscale-up toward clinical development in 2027.\n\n“Despite continued transmission of measles globally, and a reemergence in\nthe United States, physicians who see measles patients have long lamented that\nthere are no targeted approved treatments for measles. More generally, there\nhas been little, if any, innovation in how we prevent and treat measles since\n1963. As we see more and more cases, it’s clear that Americans, as well as\nthe international community, need additional prevention options for measles as\nwell as a specific treatment,” said Michael Mina, M.D., Ph.D., Chief Medical\nOfficer and Chief Epidemiologist of Invivyd and widely cited measles\nresearcher.  “A molecule like VMS063 has the potential to transform the\nmeasles landscape by leveraging the extraordinary potential of monoclonal\nantibodies that can, with one molecule, provide both prevention and treatment\nto fill these gaps. We are excited to interact with the scientific and public\nhealth community at IDWeek 2026™, as well as leaders across public health\nmore generally, and we are rapidly advancing this program toward clinical\ndevelopment.”\n\nAt IDWeek 2026™, Invivyd will present data describing that VMS063 binds a\nhighly conserved epitope of the MeV-F protein, stabilizing its pre-fusion\nconformation, supporting a mechanism of neutralization through inhibition of\nmembrane fusion. Invivyd characterized the properties of VMS063 including its\nhighly potent in vitro neutralization activity against historical and\ncontemporary MeV variants, including the highest circulating contemporary\ngenotypes, B3 and D8, in both authentic virus and pseudovirus neutralization\nassays.\n\nThe United States is facing a critical measles virus inflection point in 2026,\nwith measles incidence reaching levels not seen in decades. As of October\n2026, U.S. disease burden is nearly double that seen in 2025. As pediatric and\ncommunity vaccination rates dip, a significant immunity gap has emerged. More\nthan nine million school-aged children are estimated to be unprotected against\nmeasles in the U.S. today along with many millions more adults who are immune\ncompromised. More, as one of the most infectious viruses known to exist, and a\nvirus uniquely capable of destroying human immunologic memory, measles has the\npotential to impose a substantial burden on the healthcare system as infection\nspreads.  \n\nIDWeek 2026™ is an annual meeting of the Infectious Diseases Society of\nAmerica (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the\nHIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society\n(PIDS). IDWeek features the latest science and bench-to-bedside approaches in\nprevention, diagnosis, treatment and epidemiology of infectious diseases,\nincluding HIV, across the lifespan. IDWeek 2026™ takes place Oct. 21-24 at\nthe Walter E. Washington Convention Center (801 Allen Y. Lew Place NW) in\nWashington, D.C. For more information, visit www.idweek.org.\n\nAbout VMS063\nVMS063 is a novel, highly potent, half-life-extended, high resistance barrier\nmeasles monoclonal antibody candidate engineered via Invivyd’s proprietary\nantibody discovery platform to target a highly conserved protein of measles\nvirus. VMS063 targets the measles Fusion (F) protein and is designed to lock\nthe trimeric measles Fusion protein into a pre-fusion configuration, thereby\npreventing cell entry, similar to approved pediatric respiratory syncytial\nvirus (RSV) monoclonal antibodies. VMS063 could be the first precision therapy\nfor measles, as well as a potentially important passive preventive option to\nsupplement or enhance measles vaccination.\n\nAbout Invivyd \nInvivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to\ndelivering protection from serious viral infectious diseases, beginning with\nSARS-CoV-2. Invivyd deploys a proprietary integrated technology platform\nunique in the industry designed to assess, monitor, develop, and adapt to\ncreate best in class antibodies. In March 2024, Invivyd received emergency use\nauthorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its\npipeline of innovative antibody candidates. Visit https://invivyd.com/ to\nlearn more.\n\nTrademarks are the property of their respective owners.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Words such as\n“anticipates,” “believes,” “could,” “expects,”\n“estimates,” “future,” “intends,” “plans,” “potential,”\n“predicts,” “projects,” and “targets” or similar expressions (as\nwell as other words or expressions referencing future events, conditions, or\ncircumstances) are intended to identify forward-looking statements.\nForward-looking statements include statements concerning, among other things,\nplans related to the company’s measles program, and the potential of VMS063\nas a novel, potential first- and best-in-class mAb candidate being developed\nfor the treatment and prevention of measles; the potential for VMS063 to be\nthe first precision therapy for measles and a potentially important direct\nimmunization option to supplement, offer an alternative to, or enhance\nstandard measles vaccination; the company’s anticipated development and\nclinical timeline for VMS063; expectations regarding the public health\nenvironment and potential of a molecule like VMS063 to transform the measles\nlandscape; the company’s plans to develop VMS063 in either intramuscular or\nsubcutaneous forms; the company’s strategies and objectives; the company’s\nfuture prospects; and other statements that are not historical fact. The\ncompany may not actually achieve the plans, intentions, or expectations\ndisclosed in the company’s forward-looking statements, and you should not\nplace undue reliance on the company’s forward-looking statements. These\nforward-looking statements involve risks and uncertainties that could cause\nthe company’s actual results to differ materially from the results described\nin or implied by the forward-looking statements, including, without\nlimitation: the timing, progress, and results of the company’s discovery and\npreclinical development activities, including with respect to VMS063; whether\nor not any preclinical candidate identified by the company is determined to be\nsuitable for clinical development; the risk that results of nonclinical\nstudies or clinical trials may not be predictive of future results, and\ninterim data are subject to further analysis; unexpected safety or efficacy\ndata observed during preclinical studies or clinical trials; the\npredictability of clinical success of the company’s product candidates based\non neutralizing activity in nonclinical studies and the assessment of other in\nvitro properties; potential variability in neutralizing activity of product\ncandidates tested in different assays, such as pseudovirus assays and\nauthentic assays; the company’s reliance on third parties; uncertainties\nrelated to the regulatory authorization or approval process, and available\ndevelopment and regulatory pathways; changes in the regulatory environment;\nthe risk that a lack of awareness of mAb therapies and regulatory scrutiny of\nmAb therapies may adversely impact the development or commercial success of\nthe company’s product candidates; changes in expected or existing\ncompetition; the company’s reliance on third parties; complexities of\nmanufacturing mAb therapies; macroeconomic and political uncertainties; and\nwhether the company has adequate funding to meet future operating expenses and\ncapital expenditure requirements. Other factors that may cause the company’s\nactual results to differ materially from those expressed or implied in the\nforward-looking statements in this press release are described under the\nheading “Risk Factors” in the company’s Annual Report on Form 10-K for\nthe year ended December 31, 2025, and its Quarterly Report on Form 10-Q for\nthe quarter ended June 30, 2026, each as filed with the Securities and\nExchange Commission (SEC), and in the company’s other filings with the SEC,\nand in its future reports to be filed with the SEC and available at\nwww.sec.gov. Forward-looking statements contained in this press release are\nmade as of this date, and Invivyd undertakes no duty to update such\ninformation whether as a result of new information, future events or\notherwise, except as required under applicable law.\n\nThis press release contains hyperlinks to information that is not deemed to be\nincorporated by reference in this press release.\n\nContacts:\n\nMedia Relations \n(781) 208-0160\nmedia@invivyd.com\n\nInvestor Relations \n(781) 208-1747\ninvestors@invivyd.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7bf12f50-1073-4ce7-81ac-89426c07add3)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-21T11:01:00.158055096Z","server_sent_at_ms":1792580460158},"received_at":"2026-10-21T11:01:00.217Z","source_url":null},"analysis":{"id":"163307","press_release_id":"175278","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Data is preclinical only; clinical development not expected until 2027","Funding adequacy for future operating expenses flagged in forward-looking statement risks"],"eventType":"clinical_trial","narrative":"Invivyd presented preclinical data on VMS063, its investigational monoclonal antibody for treatment and prevention of measles, at IDWeek 2026.\n\nVMS063 showed potent in vitro neutralization against contemporary measles genotypes B3 and D8, with a half-life-extended profile and intramuscular or subcutaneous delivery planned.\n\nThe company has begun manufacturing scale-up toward clinical development in 2027, targeting an area with no FDA-approved treatments amid record U.S. measles incidence.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Pipeline optionality in an untapped measles market, but still years from the clinic."},"keyFigures":{"drugName":"VMS063","phaseOfTrial":"Preclinical (clinical development planned 2027)","customDimensions":{"clinical_entry_year":2027}},"quotedText":"A molecule like VMS063 has the potential to transform the measles landscape by leveraging the extraordinary potential of monoclonal antibodies that can, with one molecule, provide both prevention and treatment to fill these gaps.","namedEntities":{"people":[{"name":"Michael Mina, M.D., Ph.D.","role":"Chief Medical Officer and Chief Epidemiologist"}],"products":["VMS063"],"companies":[{"name":"Invivyd, Inc.","ticker":"IVVD"},{"name":"Infectious Diseases Society of America (IDSA)","relationship":"conference sponsor"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Preclinical-only data presentation at a scientific conference for pipeline candidate VMS063; no clinical results, regulatory action, or financing. Modest positive pipeline optionality for an early-stage biotech, but not near-term market-moving."},"tickerRelevance":{"others":[],"primary":"IVVD"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"preclinical conference data","marketCapAdjustment":"early-stage, pre-commercial revenue profile","retailFavoriteBoost":"modest — vaccine/antibody theme interest"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Invivyd presented preclinical data on VMS063, its investigational monoclonal antibody for treatment and prevention of measles, at IDWeek 2026.\n\nVMS063 showed potent in vitro neutralization against contemporary measles genotypes B3 and D8, with a half-life-extended profile and intramuscular or subcutaneous delivery planned.\n\nThe company has begun manufacturing scale-up toward clinical development in 2027, targeting an area with no FDA-approved treatments amid record U.S. measles incidence.","key_figures":{"drugName":"VMS063","phaseOfTrial":"Preclinical (clinical development planned 2027)","customDimensions":{"clinical_entry_year":2027}},"named_entities":{"people":[{"name":"Michael Mina, M.D., Ph.D.","role":"Chief Medical Officer and Chief Epidemiologist"}],"products":["VMS063"],"companies":[{"name":"Invivyd, Inc.","ticker":"IVVD"},{"name":"Infectious Diseases Society of America (IDSA)","relationship":"conference sponsor"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-21T11:01:05.107Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"preclinical conference data","marketCapAdjustment":"early-stage, pre-commercial revenue profile","retailFavoriteBoost":"modest — vaccine/antibody theme interest"}},"durationMs":4877,"modelName":"glm-5.3-flashx"}}